



# UNITED STATES PATENT AND TRADEMARK OFFICE

CL  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,255	08/15/2003	William P. Dole	52339AUSM1	3168
27586	7590	06/12/2006	EXAMINER	
BERLEX BIOSCIENCES PATENT DEPARTMENT 2600 HILLTOP DRIVE P.O. BOX 4099 RICHMOND, CA 94804-0099			WHITEMAN, BRIAN A	
		ART UNIT	PAPER NUMBER	
		1635		
DATE MAILED: 06/12/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/642,255	DOLE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Brian Whiteman	1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### **Status**

- 1)  Responsive to communication(s) filed on \_\_\_\_.
- 2a)  This action is **FINAL**.                            2b)  This action is non-final.
- 3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### **Disposition of Claims**

- 4)  Claim(s) 1-41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5)  Claim(s) \_\_\_\_ is/are allowed.
- 6)  Claim(s) \_\_\_\_ is/are rejected.
- 7)  Claim(s) \_\_\_\_ is/are objected to.
- 8)  Claim(s) 1-41 are subject to restriction and/or election requirement.

#### **Application Papers**

- 9)  The specification is objected to by the Examiner.
- 10)  The drawing(s) filed on \_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### **Priority under 35 U.S.C. § 119**

- 12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a)  All    b)  Some \* c)  None of:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### **Attachment(s)**

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. ____.
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
Paper No(s)/Mail Date ____.	6) <input type="checkbox"/> Other: ____.

## DETAILED ACTION

Claims 1-41 are pending.

### *Election/Restrictions*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-31, 35, 36, and 38-41, drawn to an ex vivo gene therapy method for treating critical limb ischemia (CLI), classifiable in class 424, subclass 93.21.
- II. Claims 1-30, 32-36, and 38-41, drawn to an in vivo gene therapy method for treating critical limb ischemia (CLI), classifiable in class 424, subclass 93.2.
- III. Claims 37-41, drawn to a method of treating CLI comprising administering an effective amount of an eNOS polypeptide to a patient, classifiable in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). The instant specification does not disclose that the inventions are capable of use together. The ex vivo gene therapy method (group I), an in vivo gene therapy method (group II), and polypeptide method (group III) are all unrelated as they comprise distinct steps and utilize different products which demonstrates that each method has a different mode of operation. Each invention performs this function using a structurally and functionally divergent material. For ex vivo gene therapy using the polynucleotide, autologous cells may be used. For in vivo gene therapy using the polynucleotide, viral vectors may be used. For treatment of CLI using the polypeptide, the

polypeptide is administered to a patient having CLI using any mode of administration.

Therefore, each method is divergent in materials and steps. For these reasons the Inventions I, II, and III are patentably distinct.

Furthermore, the distinct steps and products require separate and distinct searches. The inventions of Groups I, II and III have a separate status in the art as shown by their different classifications. As such, it would be burdensome to search the inventions of Groups I, II and III together.

Because these inventions are distinct for the reasons given above and the search required for each Group listed above is not required for any other Group listed above and the search for each group is not co-extensive, restriction for examination purposes as indicated is proper.

It would be unduly burdensome for the examiner to search and consider patentability of all of the presently pending claims, a restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

If applicant elects either group I or group II, applicants are further required to elect a species from the following:

This application contains claims directed to the following patentably distinct species: angiogenic factors are selected from a group of angiogenic factors consisting of: HGF, VEGF, FGF, Endothelial Growth Factor, Epidermal Growth Factor, Platelet-Derived Growth Factor,

Art Unit: 1635

TGF-alpha, TGF-beta, PDGF, TNA-alpha or IGF, Del-I. The species are independent or distinct because each angiogenic factor has a distinct structure.

Applicant is required to elect one or more specific angiogenic factors from claim 30.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 29 is generic.

**Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added.** An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

If applicant elects either group I or II, applicants are further required to elect a species from the following: eNOS polypeptide comprises a mutation at a position corresponding to amino acid residue 495 of SEQ ID NO: 1; eNOS polypeptide comprises a mutation at a position corresponding to amino acid residue 1177 of SEQ ID NO: 1; eNOS polypeptide comprises a mutation at a position corresponding to amino acid residues 495 and 1177 of SEQ ID NO: 1; and

eNOS polypeptide comprises a mutation at a position corresponding to amino acid residues 2, 495, 1177 of SEQ ID NO: 1.

This application contains claims directed to the following patentably distinct species: The species are independent or distinct because each angiogenic factor has a distinct structure.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 4, 35, and 36 are generic.

If applicant elects group III, applicants are further required to elect a species from the following: eNOS polypeptide comprises a mutation at a position corresponding to amino acid residue 495 of SEQ ID NO: 1; eNOS polypeptide comprises a mutation at a position corresponding to amino acid residue 1177 of SEQ ID NO: 1; eNOS polypeptide comprises a mutation at a position corresponding to amino acid residues 495 and 1177 of SEQ ID NO: 1; and eNOS polypeptide comprises a mutation at a position corresponding to amino acid residues 2, 495, 1177 of SEQ ID NO: 1.

This application contains claims directed to the following patentably distinct species: The species are independent or distinct because each angiogenic factor has a distinct structure.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 37 is generic.

Art Unit: 1635

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 § 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764. The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras, SPE - Art Unit 1635, can be reached at (571) 272-4517.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Fax Center number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Brian Whiteman

*Brian Whiteman*

**BRIAN WHITEMAN**  
**PATENT EXAMINER**